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Identification of over 500 epigenetic regulators in humans raises an interesting question regarding how chromatin dysregulation con-
tributes to different diseases. Bromodomain and PHD finger-containing protein 1 (BRPF1) is a multivalent chromatin regulator possess-
ing three histone-binding domains, one non-specific DNA-binding module, and several motifs for interacting with and activating three
lysine acetyltransferases. Genetic analyses of fish brpf1 and mouse Brpf1 have uncovered an important role in skeletal, hematopoietic,
and brain development, but it remains unclear how BRPF1 is linked to human development and disease. Here, we describe an intellectual
disability disorder in ten individuals with inherited or de novo monoallelic BRPF1 mutations. Symptoms include infantile hypotonia,
global developmental delay, intellectual disability, expressive language impairment, and facial dysmorphisms. Central nervous system
and spinal abnormalities are also seen in some individuals. These clinical features overlap with but are not identical to those reported for
persons with KAT6A or KAT6Bmutations, suggesting that BRPF1 targets these two acetyltransferases and additional partners in humans.
Functional assays showed that the resulting BRPF1 variants are pathogenic and impair acetylation of histone H3 at lysine 23, an abun-
dant but poorly characterized epigenetic mark. We also found a similar deficiency in different lines of Brpf1-knockout mice. These data
indicate that aberrations in the chromatin regulator gene BRPF1 cause histone H3 acetylation deficiency and a previously unrecognized
intellectual disability syndrome.Introduction
Epigenetic regulation is essential for human development
and becomes aberrant in different diseases. The human
genome encodes over 500 epigenetic regulators.1–3 To date,
~30 chromatin modifiers have been associated with human
diseases, including the ATP-dependent helicases CHD4,
CHD7, CHD8, SMARCA2, SMARCA4, and ATRX;4–6 the
DNA methyltransferases DNMT1 and DNMT3b;4 the his-
tone methyltransferases EZH2 and KMT3B;4 the lysine
acetyltransferases CREBBP, EP300, KAT6A, KAT6B, and
ESCO2;4,7–14 and the histone deacetylases HDAC4 and
HDAC8.15,16 By contrast, disease association remains
much less clear for hundreds of chromatin readers that
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 2017 American Society of Human Genetics.cation states for chromatin-based signaling.17,18 Thus, it
is important to identify disease links for such chromatin
readers. Bromodomain and PHD finger-containing pro-
tein 1 (BRPF1) is a multivalent chromatin reader composed
of multiple nucleosome-binding modules, including
double PHD fingers (linked with a C2HC zinc knuckle),
a bromodomain, and a PWWP domain.19–21 The PHD
fingers and zinc knuckle form a bivalent nucleosome-bind-
ing unit, known as the PZP (PHD finger–zinc knuckle–
PHD finger) domain.22,23 In addition, BRPF1 possesses two
enhancer of polycomb (EPC)-like motifs flanking the PZP
domain.19–21 Through one of these EPC-like motifs and its
N-terminal region, BRPF1 interacts with and activates three
histone acetyltransferases, KAT6A, KAT6B, and KAT7.19–21
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sequence motifs mediating interaction with histone
acetyltransferases.
Zebrafish and mouse genetic studies have shown that
Brpf1 is essential for embryo survival, hematopoiesis,
head patterning, and brain development.24–29 Moreover,
mutations in KAT6A (MIM: 601408) and KAT6B (MIM:
605880) have recently been discovered inmultiple individ-
uals with several developmental disorders characterized by
intellectual disability and other abnormalities.7–13 Thus,
an interesting question is whether mutations of human
BRPF1 (MIM: 602410) cause similar developmental anom-
alies. Here, we report that heterozygous missense,
nonsense, and reading frameshift mutations in this gene
cause a neurodevelopmental disorder characterized by
congenital hypotonia, global developmental delay, intel-
lectual disability, and facial dysmorphisms. We show that
these mutations cause deficiency of histone H3K23 acety-
lation and provide evidence that BRPF1 acts through
KAT6A and KAT6B to govern this chromatin modification
in vitro and in vivo. Together, this study and the recent re-
ports on individuals with KAT6A and KAT6Bmutations7–13
indicate an emerging group of developmental disorders
caused by aberrant histone H3 acetylation.Subjects and Methods
Human Subjects
Families gave consent for studies approved by the CHU Sainte-
Justine Institutional Review Board or by the institutional review
boards of the DDD (Decipher Developmental Disorder) Study, the
CAUSES (Clinical Assessment of theUtility of Sequencing andEval-
uation as a Service) Study, or the Leiden University Medical Center
and Maastricht University Medical Center. Written informed con-
sent was obtained for all ten individuals involved in this study.
Exome and Sanger Sequencing
Individual P1’s exome sequencing was performed as a part of the
CAUSES study. Clinical exome sequencing of individual P2 was
carried out at Baylor Genetics. For individual P3 (sibling of individ-
ual P2), only Sanger sequencing of a candidate mutation was done
at Baylor Genetics. Clinical exome sequencing for individuals P4
and P5 was performed at GeneDx. Exome sequencing of individ-
uals P6 and P10 was carried out at Leiden University Medical
Center and Maastricht University Medical Center, respectively.
Individuals P7, P8, and P9 were subject to research exome
sequencing as a part of the DDD study. After exome sequencing,
PCR fragments were amplified from genomic DNA or reversely
transcribed cDNA to confirm BRPF1 mutations.
Lymphoblastoid Cell Line Preparation
Lymphoblastoid cell lines were established and cultured as
described previously.30
Animal Study Approval
Mice used were in the C57BL/6J genetic background. The Brpf1f
allele contains two loxP sites flanking exons 4–6 of Brpf1.25,27,28
EIIa-Cre-mediated total knockouts, as well as forebrain-specific
and hematopoietic-specific knockouts, have been described else-92 The American Journal of Human Genetics 100, 91–104, January 5,where.26–29 To generate epiblast-specific knockouts, Brpf1f/f mice
were mated with the Meox2-Cre strain (Jackson Laboratory,
003755; Bar Harbor). Knockout efficiency was verified by genomic
PCR and/or quantitative reverse-transcription PCR (qRT-PCR) as
previously described.26–29,31 Mouse-related procedures were per-
formed according to the Animal Use Protocol 5786, which was re-
viewed and approved by the Facility Animal Care Committee of
McGill University.Immunoprecipitation and Histone Acetylation Assays
An expression plasmid for FLAG-tagged KAT6A was transfected
into HEK293 cells, along with expression vectors for HA-tagged
BRPF1, ING5, and MEAF6, as specified. About 48 hr after transfec-
tion, cells were washed twice with PBS, and soluble protein ex-
tracts were prepared for affinity purification on anti-FLAG M2
agarose (Sigma) as previously described.20,31 The FLAG peptide
was used to elute bound proteins for immunoblotting with anti-
FLAG and -HA antibodies or for acetyltransferase activity determi-
nation. Acetylation of HeLa oligonucleosomes was performed as
previously reported.20,31 After acetylation reactions, immunoblot-
ting was carried out to detect histone H3 or its site-specific acety-
lation and was performed with anti-histone H3 (Abcam,
ab1791), anti-H3K9ac (Abcam, ab10812), anti-H3K14ac (EMD
Millipore, 07-353), anti-H3K18ac (EMD Millipore, 07-354), and
anti-H3K23ac (EMD Millipore, 07-355) antibodies.Fluorescence Microscopy
For analysis of subcellular localization, expression plasmids for
EGFP-BRPF1 and its mutants were transiently transfected into
HEK293 cells with or without those for KAT6A, ING5, and
MEAF6, as specified in Figure S4. About 16 hr after transfection,
live green fluorescence signals were examined under a fluores-
cence microscope, and fluorescence images were captured for
further processing as previously described.31qRT-PCR and Regular PCR
For analysis of nonsense-mediated mRNA decay (NMD), control
and mutant lymphoblastoid cells and fibroblasts were prepared
for RNA extraction. RNA was reversely transcribed with the
QuantiTect Reverse Transcription Kit (QIAGEN). qRT-PCR was
performed on Realplex2 (Eppendorf) with the Green-2-Go
qPCR Mastermix (BioBasic). Primers were designed on the web-
based IDT real-time PCR primer designer and synthesized by
IDT Biotechnology. BR27 (50-TTT CCC GAA TTC AAG CTG
CCA GAG GTG GTC TA-30) and BR20 (50-GGG CCC AAG CTT
AGT CCT CCT CGT CCA TGT C-30) were for amplification of
the region corresponding to the N-terminal part of BRPF1,
whereas BR11 (50-G GCA CGG AAG AAT TCC TGG CAG AGA
A-30) and BR10 (50-TTT CCC AAG CTT AGCT GTG CAG CCT
CTG CAT-30) were for a region encoding the C-terminal part of
BRPF1.
To determine whether NMD definitely degradates the mutated
BRPF1 transcript, cDNA prepared from fibroblasts cultured from
a skin biopsy of individual P5 was used for PCR amplification
with primers BR419 (50-TTG AGC ACA TCC CAC CAG CT-30)
and BR421 (50-TGT TCT TTA AGGGCC CAG TT-30). The amplified
fragment was gel purified for Sanger sequencing. To verify her het-
erozygous mutation, genomic DNA from this individual and her
parents was used for PCR amplification with primers BR419 and
BR420 (50-GTG GTG GGA TGC AGG GCA CT-30). DNA fragments
were gel purified for sequencing.2017
Table 1. Identification of BRPF1 Mutations in Ten Individuals
Individual Mutation (GenBank: NM_001003694.1) Substitution in BRPF1 Origin of Mutation
P1 c.362_363delAG p.Glu121Glyfs*2 de novo
P2 c.942_955del p.Trp315Leufs*26 parental samples not available; biological mother
affected by intellectual disability and father by cerebral
palsyP3 c.942_955del p.Trp315Leufs*26
P4 c.1108C>T p.Pro370Ser mosaic in unaffected mother; mosaicism, 7% in blood
DNA, based on exome sequencing reads (21/293)
P5 c.1363C>T p.Arg455* de novo
P6 c.1688_1689del p.His563Profs*8 de novo
P7 c.1883_1886dup p.Gln629Hisfs*34 de novo
P8 c.2497C>T p.Arg833* de novo
P9 c.2915dupC p.Met973Asnfs*24 de novo
P10 c.3298C>T p.Arg1100* de novoStatistical Analysis
Statistical analysis was performed with an unpaired two-tailed Stu-
dent’s t test. p < 0.05 was considered to be statistically significant.
Graphs were generated with GraphPad Prism 6 (Graphpad
Software).Results
Identification and Clinical Features of Ten Subjects
with BRPF1 Mutations
Mutations in KAT6A and KAT6B have recently been discov-
ered in dozens of individuals with intellectual disability
and congenital abnormalities.7–13 Our recent mouse ge-
netic studies have shown that Brpf1 is essential for embryo
survival, hematopoiesis, and brain development.25–29
Together, these new findings raise the interesting question
of whether BRPF1mutations cause developmental anoma-
lies. To address this question, we sought to leverage exome
sequencing that had been carried out on a clinical or
research basis at different institutions around the world.
In addition to the use of prior collaborations, we employed
newweb-basedmatching tools such as Genematcher32 and
Decipher33 to identify individuals with mutations in
BRPF1. In the process, we identified ten subjects carrying
nine heterozygous mutations in the gene (Table 1). These
subjects were from nine different families. Seven muta-
tions were de novo (individuals P1 and P5–P10; Table 1
and Figure S1). As for the remaining two mutations, indi-
vidual P4 inherited the c.1108C>T mutation (GenBank:
NM_001003694.1) from his mother, who was mosaic for
the mutation (mosaicism, 7% in blood DNA; Tables 1
and S1). Individuals P2 and P3 are adopted siblings whose
biological mother is affected with intellectual disability.
The siblings share the same variant (c.942_955del; Tables
1 and S1), which is presumed to be maternal in origin,
although their biological mother is unavailable for testing.
Global developmental delay, expressive language impair-
ment, and intellectual disability were observed in all
individuals (Tables 2 and S1). As shown in Figure 1A, facialThe Amedysmorphisms include a flat facial profile, a round face, a
broad root of the nose, widely spaced eyes (with down-
slanting palpebral fissures), ptosis, and blepharophimosis.
Amajority of the ten individuals have hypotonia and gross
and fine motor delay. Five of them had neonatal feeding
issues. Four have epilepsy. In addition, one individual had
episodes of staring spells consistent with absence seizures,
but electroencephalogram (EEG) only showed high voltage
hypnogogichypersynchrony,without epileptiformactivity
(Tables 1 and S1). Another individual displayed EEG abnor-
malitieswhen treatedwith oxcarbazepine, but did not have
clinical seizures (Tables 1 and S1). Some individuals had
MRI anomalies; two had white matter hyper-intensity and
two had a paucity of white matter, including thinning of
the corpus callosum in one of them (Figure 1B and Table 2).
These results suggest abnormal myelination in patients
with BRPF1 mutations. Interestingly, myelination and
corpus callosum defects are present in forebrain-specific
Brpf1-knockout mice.28 Three individuals also displayed
C2-C3 spinal fusions (Table S1),which is consistentwithde-
regulatedHox expression upon Brpf1 deletion inmice28 and
with skeletal abnormalities in Brpf1-null zebrafish.24 Addi-
tional dysmorphisms, malformations, and clinical issues
in the ten individuals are detailed in Table S1.
BRPF1 Mutations Are Predicted to Generate Different
Types of Variants
Among the BRPF1 mutations, one is missense and the re-
maining eight are nonsense mutations or reading frame-
shifts that lead to C-terminal truncations of the protein
(Table 1 and Figure 2A). The missense mutation in individ-
ual P4 (p.Pro370Ser [c.1108C>T]; Table 1 and Figure 2A)
alters the codon for Pro370, which is invariant from
Drosophila to humans (Figure 2B) and is located within a
loop of the PZP domain important for non-specific binding
to the DNA backbone of nucleosomes (Figure 2C).23
Moreover, it is almost invariant in PZP domains from nine
otherhumanproteins, including three JADEproteins, three
histone demethylases, and three zinc finger proteinsrican Journal of Human Genetics 100, 91–104, January 5, 2017 93
Table 2. Summary of Major Clinical Features in Ten Individuals with BRPF1 Mutations
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Neonatal feeding difficulties N Y NA Y N N Y N N Y
Hypotonia Y Y NA Y Y Y NA N Y Y
Gross motor delay Y Y Y Y Y Y Y N Y Y
Fine motor delay Y Y Y N Y N U Y Y U
Language delay Y Y Y Y Y Y Y Y Y Y
GDD or ID Y Y Y Y Y Y Y Y Y Y









nl nl nl NA NA NA decreased
WM
nl
Flat facial profile Y N Y Y Y N U Y Y Y
Round face Y Y Y N Y N Y Y N Y
Broad root of the nose Y Y Y Y Y N Y Y Y Y
Widely spaced eyes Y Y Y Y Y N Y Y Y Y
Down-slanting
palpebral fissures
N Y N N N N Y N Y Y
Ptosis Y N Y N Y Y Y N N Y
Blepharophimosis U N Y Y Y N NA N N Y
Spinal anomalies Y Y Y N Y NA NA N N NA
Joint hypermobility Y N N N Y Y Y Y Y N
See Table S1 for more details. Abbreviations are as follows: CC, corpus callosum; GDD, global developmental delay; ID, intellectual disability; N, no; NA, data not
available, nl, normal; U, unknown; WM, white brain matter; Y, yes.(AF-10, AF-17, and PHF14) (Figure S2). All eight trun-
cating mutations encode variants lacking important
structural domains of BRPF1 (Figure 2A). The variants
p.Glu121Glyfs*2 (c.362_363delAG) (individual P1;
Table 1), p.Trp315Leufs*26 (c.942_955del) (individuals P2
and P3), p.Arg455* (c.1363C>T) (individual P5), and
p.His563Profs*8 (c.1688-1689del) (individual P6) are devoid
of the ING5- and MEAF6-interacting domain (Figure 2A).
On the basis of published data,20 these variants are predicted
to be unable to form tetrameric complexes with KAT6A
(or KAT6B), ING5, and MEAF6. By contrast, the ING5- and
MEAF6-interacting domain is intact in the remain-
ing four truncation variants, p.Gln629Hisfs*34 (c.1883_
1886dup), p.Arg833* (c.2497C>T), p.Met973Asnfs*24
(c.2915dupC), and p.Arg1100* (c.3298C>T) (individuals
P7–P10, respectively; Table 1 and Figure 2A). These fourmu-
tants are expected to form tetrameric complexeswithKAT6A
(or KAT6B), ING5, and MEAF6. Therefore, the nine muta-
tions appear to generate three distinct groups of variants,
suggesting that themutationsmight deregulate BRPF1 func-
tions through different mechanisms.
BRPF1 Loss Reduces Histone H3K23 Acetylation
In Vivo
Through the EPC-like motif N-terminal to the PZP domain
and a conserved region further N-terminal to this motif,
BRPF1 interacts with and activates three histone acetyl-94 The American Journal of Human Genetics 100, 91–104, January 5,transferases, KAT6A, KAT6B, and KAT7.19–21 Drosophila
Enok (a fly acetyltransferase with a catalytic domain highly
homologous to those of KAT6A and KAT6B) and Br140
(orthologous to BRPF1) are crucial for histone H3K23
acetylation.38,39 We found that BRPF1 is also important
for histone H3K23 acetylation in the mouse bone
marrow.29 In agreement with this, H3K23 acetylation was
defective in thymus and spleen protein extracts from
hematopoietic-specific Brpf1- knockout pups (Figures 3A
and 3B). Moreover, similar defects were present in dorsal
cortex extracts of forebrain-specific Brpf1-knockout pups
(Figure 3C) and protein extracts of epiblast-specific Brpf1-
knockout embryos (Figure 3D, lanes 1 and 4–6). Interest-
ingly, heterozygous mutant embryos also displayed
reduced H3K23 acetylation (Figures 3D and 3E, compare
lanes 1–3), which is relevant to monoallelic mutations in
the ten individuals (Table 1). Furthermore, H3K23 acetyla-
tionwas not detectable in Brpf1/mouse embryonic fibro-
blasts (Figure 3F). By contrast, histone H3K9 and H3K14
acetylation was less consistently affected in different
Brpf1-knockout samples (Figures 3A–3F). Therefore, mouse
Brpf1 governs H3K23 acetylation in different tissues and
cells in vivo.
These results prompted us to investigate whether his-
tone H3K23 acetylation is affected in cells from individ-
uals with BRPF1 mutations. Lymphoblastoid cells from
individual P4 (p.Pro370Ser; Table 1) showed reduced2017
Figure 1. Facial and Brain Characteristics of Individuals with BRPF1 Mutations
(A) Photos for eight individuals. The photos are not in the same scale. Ages of the individuals when the photos were taken are as follows:
P1, 6 years and 5 months; P2, 13 years and 3 months; P4, 10 years and 6 months; P5, 8 years and 3 months; P6, 4 years; P7, 12 years and
6 months; P9, 8 years; P10, 12 years.
(B) Brain magnetic resonance imaging (MRI) images of individuals P2 and P9.H3K23 acetylation (~50% of the control; Figure 3G). In
comparison, qRT-PCR revealed no decrease in the amount
of BRPF1 mRNA in mutant cells (Figure S3A). We also
obtained a skin biopsy from individual P5 (p.Arg455*;The AmeTable 1) for preparation of fibroblasts. As shown in
Figure 3H, H3K23 acetylation in the fibroblasts also
decreased to ~50% of the control. These results indicate
that two mutations lead to decreased H3K23 acetylationrican Journal of Human Genetics 100, 91–104, January 5, 2017 95
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Figure 2. Domain Organization of BRPF1 and Its Variants from Individuals with Developmental Anomalies
(A) Schematic representation of BRPF1 and nine variants as identified in ten individuals. See Table 1 for DNA sequence changes in the
individuals. BRPF1 possesses multiple modules, including the PZP domain, bromodomain, and PWWP domain, for chromatin associa-
tion. The PZP domain comprises two PHD fingers linked with a C2HC zinc finger. The first PHD finger recognizes the N terminus of his-
tone H3.21,23,34 The C2HC zinc knuckle and the second PHD finger form a non-specific DNA binding domain.22,23 The bromodomain
has acetyllysine-binding ability,35 and the PWWP domain targets trimethylated histone H3.36,37 The EPC-like motif C-terminal to
the PZP domain is essential for formation of a stable trimeric complex with ING5 and MEAF6.19–21 Through the EPC-like motif N-ter-
minal to the PZP domain and a conserved region further N-terminal to this motif, BRPF1 interacts with and activates KAT6A, KAT6B,
and KAT7.19–21 Unlike p.Pro370Ser, the other eight variants contain C-terminal truncations due to nonsense or reading-frameshift mu-
tations. These mutations are not located within the last coding exon and might trigger NMD in vivo. Abbreviations are as follows: CH,
C2H2 zinc finger; BN, conserved BRPF N-terminal domain; EPC, enhancer of polycomb-like motif; NLS, nuclear localization signal.
(B) Sequence alignment of human BRPF1 with its paralogs (BRPF2 and BRPF3), as well as the orthologs from zebrafish (z),Xenopus (x), sea
urchin (s), Drosophila (d), and C. elegans (Lin-49). There is one ortholog per organism from the worm to Xenopus, but there are three in
zebrafish. Pro370 of BRPF1 and its corresponding residues in its paralogs and orthologs are boxed in red.
(C) Pro370 is located within a loop connecting the C2HC knuckle to the second PHD finger. PHD1 recognizes the free N terminus of
histone H3,21,23,34 whereas the C2HC zinc knuckle and PHD2 form a module for non-specific interaction with the DNA backbone of
the nucleosome.23 The structural model was generated based on a published report,23 with kind help of Tatiana G. Kutateladze.
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Figure 3. BRPF1 Loss Reduces Histone
H3K23 Acetylation In Vivo
(A and B) Histone H3 acetylation in
thymus and spleen protein extracts from
control and hematopoietic-specific Brpf1-
knockout mice.
(C) Histone H3 acetylation in dorsal
cortical extracts from heterozygous and
forebrain-specific Brpf1 knockouts.
(D) Histone H3 acetylation in protein ex-
tracts from wild-type and epiblast-specific
Brpf1-knockout embryos at embryonic
day 10.5 (E10.5).
(E) Quantification of H3K23 acetylation in
proteins extracts from wild-type and
epiblast-specific Brpf1 knockout embryos
at E10.5. The blot was from the same exper-
iment as shown in (D), but the exposure
time was shorter than the bottom image
in (D). The quantification was performed
with NIH ImageJ.
(F) Histone H3 acetylation in protein ex-
tracts from control and Brpf1-knockout
mouse embryonic fibroblasts (MEFs). The
fibroblasts were prepared from control
and tamoxifen-inducible knockout em-
bryos at E15.5.27
(G) Histone H3 acetylation in protein ex-
tracts from control and p.Pro370Ser lym-
phoblastoid cells.
(H) Histone H3 acetylation in protein
extracts from control and p.Arg455*
fibroblasts.in individuals P4 and P5 (Table 1 and Figures 3G and
3H). Consistent with this, RNAi knockdown showed that
BRPF1 is important for H3K23 acetylation in human
U2OS cells.40
NMD degradates a premature stop codon-containing
transcript expressed in Brpf1-knockout mice.26,28,29 The
mutation in individual P5 introduces a stop codon in a
middle exon (Figure 2A) and might thus trigger NMD. To
investigate this, we first performed qRT-PCR to analyze
BRPF1 mRNA amounts in the control and mutant
fibroblasts. One primer set, but not the other, detected
some decrease of BRPF1 mRNA in the mutant cells
(Figure S3B). To resolve this difference, cDNA from the
mutant fibroblasts was prepared and sequenced. The re-
sults revealed that the wild-type and mutant alleles were
similarly expressed (Figure S1C), indicating that NMD is
not at play with the mutant transcript in fibroblasts
from individual P5. To substantiate this, we compared lym-
phoblastoid cells from this individual and her parents.
qRT-PCR analysis of BRPF1 mRNA detected no difference
between the mutant and control cells (Figure S3C).
Furthermore, we analyzed lymphoblastoid cells from indi-
vidual P2, also carrying a premature stop codon in the
mutant allele (Table 1). qRT-PCR analysis of BRPF1 mRNA
detected no difference between the mutant and control
cells (Figure S3D). Together, these results suggest thatThe AmeNMD does not apply to the mutant transcripts in individ-
uals P2 and P5. Notably, a similar conclusion has been
reached for KAT6A and KAT6B mutations.9,12
Impact of BRPF1 Mutations on Histone H3K23
Acetylation In Vitro
To delineate further the molecular mechanisms by which
the BRPF1 mutations affect H3K23 acetylation, we engi-
neered seven variants encoded by the mutations and
analyzed the impact on formation of tetrameric complexes
with KAT6A (Figure 4). The variants were produced tran-
siently in HEK293 cells with KAT6A, ING5, and MEAF6
for co-immunoprecipitation. BRPF1 serves as a scaffold
protein to bridge interaction of KAT6A and KAT6B with
ING5 and MEAF6.19,20 Exogenous BRPF1 promoted pro-
duction of ING5 and MEAF6 (Figure 4A, top panel, lanes
1 and 2). We observed similar effects with p.Pro370Ser,
p.Gln629Hisfs*34, p.Arg833*, and p.Arg1100* (Figures
4A, 4C, and 4D, top panels). Moreover, like wild-type
BRPF1, these four variants form tetrameric complexes
with KAT6A, ING5, and MEAF6 (Figures 4A, lanes 2 and
3, and 4D, lanes 4–7). By contrast, p.Glu121Glyfs*2,
p.Trp315Leufs*26, and p.Arg455* failed to promote expres-
sion of ING5 and MEAF6 (Figures 4C and 4D, top panel).
p.Glu121Glyfs*2 was not produced as well as the wild-
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Figure 4. Functional Characterization of BRPF1 Variants In Vitro
(A) Interaction of BRPF1 and the variants with KAT6A, ING5, andMEAF6. KAT6Awas produced in HEK293 cells as a FLAG-tagged fusion
protein along with HA-tagged BRPF1 (or the p.Pro370Ser variant), ING5, andMEAF6 as indicated. Soluble protein extracts were prepared
for affinity purification on anti-FLAG agarose, and bound proteins were eluted with the FLAG peptide for immunoblotting with anti-
FLAG and -HA antibodies.
(B) Histone acetylation assays. HeLa oligonucleosomes were used as substrates for acetylation by proteins affinity purified in (A). Acet-
ylation of histone H3 was detected with antibodies recognizing histone H3 and its acetylated forms as indicated.
(C and D) Same as (A) except that different BRPF1 variants were analyzed. Unexpectedly, the variant p.Trp315Leufs*26 still showed
strong interaction with MEAF6; whether this is due to the extra 26 residues introduced after the reading frameshift remains unclear.
(E) Histone acetylation assays. Proteins affinity-purified in (D) were used for the enzymatic assays as in (B).KAT6A to form a tetrameric complex with ING5 and
MEAF6 (Figure 4C). The remaining two variants interacted
with KAT6A similarly to wild-type BRPF1 (Figure 4D, lanes98 The American Journal of Human Genetics 100, 91–104, January 5,1–3 and 7). As expected, given its lack of the ING5- and
MEAF6-interacting domain (Figure 2A), p.Arg455* failed
to mediate the interaction of KAT6A with ING5 and2017
MEAF6 (Figure 4D, lanes 3 and 7). Unexpectedly,
pTrp315Leufs*26 was still able to interact with MEAF6
(compare lanes 2 and 7).Whether this is due to the extra 26
residues introduced by the reading frameshift remains un-
clear. These results support that the nine variants (Table 1
and Figure 2A) form different groups according to the
ability to form tetrameric complexes with KAT6A, ING5,
and MEAF6.
We next investigated whether the BRPF1 variants stimu-
late the acetyltransferase activity of KAT6A. As shown in
Figure 4B (lanes 1 and 2), wild-type BRPF1 promoted
H3K23 acetylation by KAT6A when oligonucleosomes
were used as the substrate. By contrast, p.Pro370Ser failed
to do so (Figure 4B, lanes 1–3). This is consistent with
reduced H3K23 acetylation in lymphoblastoid cells pre-
pared from individual P4 (Figure 3G). These results attest
to the importance of the DNA-binding loop of BRPF1 in
regulating the acetyltransferase activity of KAT6A. Like
this mutant, the variant pTrp315Leufs*26 was inactive
in stimulating the acetyltransferase activity of KAT6A
(Figure 4E, lanes 1–4). The variant p.Arg455* showed
reduced ability to stimulate the acetyltransferase activity
of KAT6A (compare lanes 1–3 and 5). The impaired ability
of the variants pTrp315Leufs*26 and p.Arg455* is likely
due to the loss of the domain crucial for ING5 and EAF6
interaction (Figure 1A).20 By contrast, p.Gln629Hisfs*34,
p.Arg833*, and p.Arg1100* were as active as wild-type
BRPF1 in stimulating the acetyltransferase activity of
KAT6A (Figure 4E, lanes 6–8), in agreement with their
ability to form tetrameric complexes with KAT6A,
ING5, andMEAF6, similarly to wild-type BRPF1 (Figure 4D,
lanes 4–7). The variants p.Arg833* and p.Arg1100* lack the
PWWP domain, which binds to trimethylated histone H3
in vitro.36,37 Moreover, a mutant lacking this domain
causes developmental defects in zebrafish.24 Thus, the
findings on these two variants reiterate the importance
of the PWWP domain in vivo.
We also analyzed subcellular localization of BRPF1 and
its mutants by fluorescence microscopy. As reported for
NIH 3T3 fibroblasts,20 when produced alone in HEK293
cells, BRPF1 formed cytoplasmic dots but became more
nuclear with co-production of KAT6A, ING5, and
MEAF6 (Figure S4). By themselves, p.Glu121Glyfs*2 and
p.Trp315Leufs*26 presented uniform cytoplasmic distribu-
tion, whereas p.Arg455* and p.Gln629Hisfs*34 weremainly
nuclear (Figure S4). In the presence of exogenous KAT6A,
ING5, and MEAF6, these four variants were all nuclear
(Figure S4). The variant p.Arg833* formed large aggregates
in the cytoplasm but became nuclear upon co-production
of KAT6A, ING5, and MEAF6 (Figure S4). By itself, the
missense variant p.Pro370Ser showed cytoplasmic distribu-
tion different from the wild-type but translocated to the
nucleus upon co-production of KAT6A, ING5, and MEAF6
(Figure S4). Thus, the missense and truncation variants all
behaved differently from wild-type BRPF1 (Figure S4).
Together, results from determination of enzymatic activity
(Figures 3 and 4) and subcellular localization (Figure S4)The Amesupport that the BRPF1 mutations lead to pathogenicity
through different mechanisms.
Distribution of Histone H3K23 Acetylation in the
Mouse Brain
Intellectual disability in the individuals with BRPF1 muta-
tions (Tables 1, 2, and S1) suggests the importance of
BRPF1 in human brain development. In support of this,
BRPF1 was highly expressed in the brain,25 and fore-
brain-specific inactivation of mouse Brpf1 leads to defects
in the cerebrum and hippocampus.26,28 In addition,mouse
Kat6b is important for cerebral development.41 We thus
analyzed distribution of H3K23 acetylation in the mouse
brain. For this, indirect immunofluorescence microscopy
was performed on mouse brain sections. As shown in
Figure 5, fluorescence signals for H3K23 acetylation were
detectable in the cerebral cortex but enhanced in the hip-
pocampus and cerebellum. In the hippocampus, the signal
was enriched within Cornu Ammonis areas and the dentate
gyrus (Figure 5). In addition, the signals were high at
islands of Calleja located within the olfactory tubercle
(Figure 5). The cerebrum, hippocampus, and olfactory
tubercle are all important for learning and memory.
Moreover, the H3K23ac distribution is very similar to the
expression pattern of mouse Brpf1 in the brain, as deter-
mined with a knockin reporter.25 These results further
support that BRPF1 acts through H3K23 acetylation to
regulate brain functions.
BRPF1 Governs H3K23 Acetylation through KAT6A
and KAT6B
Via the EPC-like motif N-terminal to the PZP domain and
a conserved region further N-terminal to this motif
(Figure 2A), mammalian BRPF1 interacts with three his-
tone acetyltransferases, KAT6A, KAT6B, and KAT7.19–21
Although Drosophila Br140 co-purified efficiently with
Enok (homologous to KAT6A and KAT6B), Chameau
(orthologous to KAT7) was not detectable.38,39,42 An inter-
esting question is how KAT6A, KAT6B, and KAT7
contribute to BRPF1 functions in mammals. The binding
sites for these KATs are all located within the N-terminal
domain of BRPF1,19–21 so we investigated its competitive
interactionwith KAT6A and KAT7. For this, BRPF1 was pro-
duced in HEK293 cells as a FLAG-tagged fusion protein
along with HA-tagged KAT6A (or KAT7), ING5, and
MEAF6, as indicated (Figure 6A). Soluble protein extracts
were prepared for co-immunoprecipitation. As shown in
Figure 6A, the MYST domain of KAT6A formed an almost
stoichiometric complex with ING5 and MEAF6, whereas
the amount of KAT7 co-precipitated with BRPF1 was
much lower (compare lanes 4 and 6). When both acetyl-
transferases were produced together (lane 5), competition
was not obvious, supporting that they utilize distinct
binding sites. Related to this, KAT7 binds to the BN domain
of BRPF1,21 whereas KAT6A binds to a region more C-ter-
minal to the BN domain (Figure 4).20 Based on the
amount of KAT7 recovered from co-immunoprecipitationrican Journal of Human Genetics 100, 91–104, January 5, 2017 99
Figure 5. Distribution of Histone H3K23 Acetylation in the
Mouse Brain
Adult mouse brain sections were used for indirect immunofluores-
cence microscopy with the anti-H3K23ac antibody (upper), with
nuclei counterstainedwith DAPI (middle). H3K23ac signals are en-
riched in the hippocampus, cerebellum, olfactory bulb (OB), and
islands of Calleja (IC). Within the hippocampus, the fluorescence
signals were high in Cornu Ammonis (CA) areas and the dentate
gyrus (DG). Images of one representative parasagittal brain section
are shown here. MB, mid-brain. Scale bar, 1 mm.(Figure 6A), its binding to BRPF1 appeared to be much
weaker than that of KAT6A. KAT6A is paralogous to
KAT6B,20,43 so these results suggest that BRPF1 mainly
acts through KAT6A and KAT6B to control H3K23 acetyla-
tion in vivo (Figure 6B, left). These results also imply that
through altering H3K23 acetylation by these two acetyl-
transferases, BRPF1mutations cause developmental anom-
alies (Figure 6B, right).Discussion
Chromatin structure and function constitute an integral
component of epigenetic regulation. To interpret different100 The American Journal of Human Genetics 100, 91–104, January 5chromatin modification states, the human genome en-
codes several hundred chromatin readers. Some of them
have been investigated at the molecular level and in model
organisms, but very few have been associated with Mende-
lian disorders in humans. Results presented herein show
that BRPF1 mutations cause a developmental disorder in
ten individuals with an intellectual disability syndrome
(Figures 1 and 2 and Table 2). Developmental delay, intel-
lectual disability, and language impairment are consistent
with recent knockout studies showing that mouse Brpf1
is critical for embryo survival and forebrain develop-
ment.26–28 The individuals are heterozygous for the
mutations (Figures 1 and 2A). The mutated alleles are not
functional in individuals P1–P5, P7, and P8 (Figures 3, 4,
and S4), and perhaps also in individuals P6, P9, and P10
(Tables 1), so haploinsufficiency might be the pathological
mechanism, as observed in several developmental disor-
ders due to KAT6A mutations or KAT6B mutations.7–13
Some clinical features such as intellectual disability and
developmental delay reported herein are common to those
in persons with KAT6A or KAT6B mutations,7–13 but
craniofacial dysmorphisms are less striking in individuals
with BRPF1 mutations (Figure 1 and Table 2). Although
the number of patients is not large enough to draw broad
conclusions, most individuals with BRPF1 variants do
not exhibit microcephaly, as seen in persons with KAT6A
variants,12,13 or possess genital and patellar abnormalities
observed in genitopatellar syndrome (MIM: 606170) due
to KAT6B mutations.9,10 However, clinical variability
has been observed in persons with KAT6B variants,
which can present as genitopatellar syndrome or the Say-
Barber-Biesecker-Young-Simpson variant of Ohdo syn-
drome (MIM: 603736).7–11 Notably, a majority of KAT6A
and KAT6B mutations remove the serine- and methio-
nine-rich transcriptional activation domain but leave the
acetyltransferase domain intact,7–13 so they are not ex-
pected to affect global histone H3K23 acetylation per se.
This is different from themajor impact of BRPF1mutations
on histone H3K23 acetylation (Figures 2–4), raising a ther-
apeutic prospect whereby it might be beneficial to correct
this deficiency with deacetylase inhibitors.
Molecular analyses showed that the mutations impair
H3K23 acetylation (Figure 3) due to defects in activating
the acetyltransferases KAT6A and KAT6B (Figure 4)
and in maintaining proper subcellular distribution
(Figure S4). The latter is especially important for those
variants lacking the PWWP domain only (Figure 2A).
Moreover, it has been shown that the PWWP domain is
important both in vitro and in vivo.24,36,37 For H3K23 acet-
ylation, BRPF1 acts predominantly through KAT6A and
KAT6B (Figure 6A). These molecular results are consistent
with two recent reports showing that BRPF1 is important
for histone H3K23 acetylation in mouse hematopoietic
stem cells and that KAT6B is a histone H3K23 acetyltrans-
ferase in lung cancer cells.29,44 Moreover, Drosophila Enok
and Br140 are crucial for histone H3K23 acetylation.38,39
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Figure 6. BRPF1 Governs H3K23 Acetylation through KAT6A and KAT6B
(A) Competitive interaction of BRPF1with KAT6A and KAT7. BRPF1was produced in HEK293 cells as a FLAG-tagged fusion protein along
with HA-tagged KAT6A (or KAT7), ING5, and MEAF6 as indicated. For KAT6A, only its MYST domain was produced (labeled as KAT6A*).
Soluble protein extracts were prepared for affinity purification on anti-FLAG agarose, and bound proteins were eluted with the FLAG
peptide for immunoblotting with anti-FLAG and -HA antibodies.
(B) Cartoon showing how BRPF1 mutations affect histone H3K23 acetylation and cause developmental abnormalities. In individuals
without BRPF1 mutations (left), BRPF1 forms a trimeric complex with ING5 and EAF6 to control histone H3K23 acetylation by
KAT6A and KAT6B, which in turn regulate developmental programs. In individuals with BRPF1 mutations (right), BRPF1 variants fail
to exert proper control on histone H3K23 acetylation, thereby deregulating normal gene expression and developmental programs.
For simplicity, the cartoon does not illustrate additional partners that BRPF1 might have in vivo.KAT6A and KAT6B to govern H3K23 acetylation and that
mutations in BRPF1 might deregulate related epigenetic
and developmental programs (Figure 6B).
Compared to other histone acetylation sites (such as
H3K9, H3K14, H3K27, and H4K16), H3K23 is not as well
characterized. However, three recent studies have unex-
pectedly revealed that acetylation at this site is highly
abundant from C. elegans to humans,45–47 suggesting
evolutionarily conserved importance in different organ-
isms. At the mechanistic level, H3K23 acetylation serves
as a docking site for the chromatin reader TRIM24 in breast
cancer.48 This epigenetic mark also competes with H3K23
methylation and ubiquitination, both of which have
recently emerged as two important epigenetic marks.49,50
H3K23 acetylation might even interplay with H3K18
acetylation and H3K27 methylation, given the physical
proximity to these two modification sites. Furthermore, a
recent study has linked H3K23 acetylation to DNA replica-
tion and perhaps also DNA repair in Drosophila.39 Thus,
defective H3K23 acetylation in individuals with BRPF1
mutations might exert polytrophic effects on molecular
and cellular processes underlying the developmental
anomalies.
BRPF1 is conserved from worms to humans.51 Lin-49, a
related protein in C. elegans, regulates neuron asymmetry,
hindgut development, and fecundity.52 Drosophila Br140The Ameris highly homologous to mammalian BRPF1 and forms a
tetrameric complex with Enok (homologous to KAT6A
and KAT6B) to target histone H3K23 acetylation.39,42
Enok is critical for neuroblast proliferation in the fly
brain.53 Both Br140 and Enok are important for neuronal
wiring of the fly visual system too.54 Although their func-
tions in the nervous system remain unclear, both Brpf1
and Kat6a are important for maintaining pharyngeal
segmental identity and skeletal development in zebra-
fish.24,55 Both Brpf1 and Kat6b are critical for mouse brain
development.26,28,41 Consistent with this, intellectual
disability is a major clinical feature in individuals with
mutations in BRPF1 (Table 2) or KAT6B.7–11 Although the
individuals described herein carry monoallelic mutations,
no obvious phenotypes have been observed for heterozy-
gous Brpf1 mice.24–29 Similarly, although monoallelic mu-
tations in KAT6A or KAT6B cause developmental anoma-
lies, no obvious phenotypes have been reported for
heterozygous Kat6a or Kat6bmice.41,56,57 We have recently
found that Brpf1 is critical for mouse hematopoietic stem
cells and that its inactivation leads to pre-weaning lethality
as a result of acute bone-marrow failure,29 but no hemato-
logical abnormalities have been observed in the individ-
uals with BRPF1 mutations (Tables 2 and S1). Similarly,
mouse Kat6a is critical for hematopoietic stem cells,56,57
but no hematological abnormalities have been discoveredican Journal of Human Genetics 100, 91–104, January 5, 2017 101
in patients with the KAT6A mutations. One major differ-
ence is that both alleles are inactivated in knockout mice
but only one allele is affected in individuals with BRPF1
or KAT6A mutations. In addition, over 100 missense and
truncating somatic mutations in BRPF1 have been identi-
fied in different types of cancer.23,51 About one third of
these mutations are predicted to inactivate BRPF1 func-
tions, but no indications of cancer predisposition are
present in the ten individuals with BRPF1 mutations,
although the oldest is now only 17 years old (Tables 2
and S1). Thus, further studies are needed to investigate
these interesting issues.
In summary, we provide evidence that heterozygous
BRPF1 mutations cause intellectual disability and other
anomalies. The mutations affect physical and functional
interactions of BRPF1 with KAT6A and KAT6B, resulting
in deficient histone H3K23 acetylation (Figure 6B). Our
findings provide a basis for phenotypic and molecular
diagnosis of the developmental disorder with BRPF1muta-
tions, highlight the importance of this chromatin regu-
lator in human development, and shed light on functions
of its orthologs in different organisms. The findings also
suggest potential value to using Brpf1 mutant mice as pre-
clinical models for exploring treatment options. This study
on BRPF1 mutations and the recent reports7–13 on KAT6A
and KAT6Bmutations uncover an emerging group of intel-
lectual disability disorders caused by aberrant histone H3
acetylation.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.
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M. (2010). Molecular basis of histone H3K36me3 recognitionican Journal of Human Genetics 100, 91–104, January 5, 2017 103
by the PWWP domain of Brpf1. Nat. Struct. Mol. Biol. 17,
617–619.
37. Wu, H., Zeng, H., Lam, R., Tempel, W., Amaya, M.F., Xu, C.,
Dombrovski, L., Qiu, W., Wang, Y., and Min, J. (2011). Struc-
tural and histone binding ability characterizations of human
PWWP domains. PLoS ONE 6, e18919.
38. Huang, F., Paulson, A., Dutta, A., Venkatesh, S., Smolle, M.,
Abmayr, S.M., andWorkman, J.L. (2014). Histone acetyltrans-
ferase Enok regulates oocyte polarization by promoting
expression of the actin nucleation factor spire. Genes Dev.
28, 2750–2763.
39. Huang, F., Saraf, A., Florens, L., Kusch, T., Swanson, S.K., Szers-
zen, L.T., Li, G., Dutta, A., Washburn, M.P., Abmayr, S.M., and
Workman, J.L. (2016). The Enok acetyltransferase complex in-
teracts with Elg1 and negatively regulates PCNA unloading to
promote the G1/S transition. Genes Dev. 30, 1198–1210.
40. Feng, Y., Vlassis, A., Roques, C., Lalonde, M.E., González-
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42. Strübbe, G., Popp, C., Schmidt, A., Pauli, A., Ringrose, L., Bei-
sel, C., and Paro, R. (2011). Polycomb purification by in vivo
biotinylation tagging reveals cohesin and Trithorax group
proteins as interaction partners. Proc. Natl. Acad. Sci. USA
108, 5572–5577.
43. Champagne, N., Bertos, N.R., Pelletier, N., Wang, A.H., Vez-
mar, M., Yang, Y., Heng, H.H., and Yang, X.J. (1999). Identi-
fication of a human histone acetyltransferase related to
monocytic leukemia zinc finger protein. J. Biol. Chem. 274,
28528–28536.
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